4.3 Advanced Clinical Procedures: Local Anesthesia, Nitrous Oxide, and Soft Tissue Curettage

Advanced Clinical Procedures: Local Anesthesia, Nitrous Oxide, and Soft Tissue Curettage

Statutory Prerequisites: The BPC § 1909 Mandate and DHBC Course Approval

In California, the performance of invasive pharmacological and periodontic therapies represents an expanded scope of practice that carries significant legal and clinical responsibilities. Under Business and Professions Code Section 1909, a Registered Dental Hygienist (RDH) is authorized to perform three advanced clinical procedures:

1. Soft tissue curettage;
2. Administration of local anesthesia; and
3. Administration of nitrous oxide and oxygen, whether administered alone or in combination with each other.

To legally perform any of these three procedures, California law mandates two strict conditions:

• Direct Supervision: The procedure must be performed under the direct supervision of a licensed dentist who has examined the patient, diagnosed the condition, authorized the procedure, and is physically present in the treatment facility.
• Board-Approved Certification: The RDH must have successfully completed a Dental Hygiene Board of California (DHBC)–approved educational course in each specific procedure and submitted satisfactory documented proof to the Board.

While modern accredited California dental hygiene degree programs incorporate these three competencies directly into their core curriculum, out-of-state licensees or hygienists licensed prior to curriculum standardization must complete standalone board-approved continuing education courses and receive formal clearance from the DHBC before administering these modalities. Performing any of these advanced procedures without the documented board-approved course completion required by BPC § 1909, or without a dentist physically present in the treatment facility as BPC § 1902(c) requires, is practice beyond the scope of the license under BPC § 1954 and grounds for discipline under BPC §§ 1947 and 1949, up to and including revocation.

Local Anesthesia Administration: Neuroanatomy, Techniques, and Pharmacology

Local anesthesia eliminates pain transmission during non-surgical periodontal scaling, root planing, and soft tissue curettage. California RDHs are authorized to administer both local infiltration and regional nerve block injections.

Anatomical Landmarks and Injection Techniques

Mastery of regional neuroanatomy and landmark palpation is mandatory to achieve profound anesthesia while avoiding vascular punctures and neural trauma:

• Inferior Alveolar (IA) and Lingual Nerve Block: Anesthetizes mandibular teeth to the midline, the body of the mandible, buccal periodontium anterior to the first molar, and lingual soft tissues. Key anatomical landmarks include the coronoid notch (deepest concavity on the anterior border of the ramus), the pterygomandibular raphe, and the occlusal plane of the mandibular molars. Needle penetration occurs at the intersection of the horizontal plane (6–10 mm superior to the mandibular occlusal plane) and the vertical plane (two-thirds to three-fourths the distance from the coronoid notch to the pterygomandibular raphe). Bone must be gently contacted prior to depositing solution to avoid penetrating the parotid gland (which causes transient facial nerve paralysis).
• Long Buccal (Buccal) Block: Anesthetizes the buccal soft tissues adjacent to the mandibular molars. Target: mucous membrane distal and buccal to the most distal molar.
• Mental and Incisive Nerve Blocks: Target the mental foramen, typically situated between the apices of the mandibular premolars. Anesthetizes the buccal soft tissues, lower lip, chin, and (for incisive block) pulpal tissues of premolars, canines, and incisors.
• Posterior Superior Alveolar (PSA) Block: Anesthetizes maxillary molars (except the mesiobuccal root of the first molar in 28% of patients) and buccal periodontium. Landmarks: mucobuccal fold superior to the second molar, maxillary tuberosity, and zygomatic process. Insertion must be angled at 45 degrees superiorly, medially, and posteriorly. Over-insertion risks penetrating the pterygoid venous plexus or maxillary artery, causing a rapid, extensive hematoma.
• Middle Superior Alveolar (MSA) and Anterior Superior Alveolar (ASA) Blocks: Anesthetizes maxillary premolars and anterior teeth. Landmarks: mucobuccal fold superior to the second premolar and canine, respectively.
• Palatal Injections: The Greater Palatine Block (greater palatine foramen lingual to second/third molars) and Nasopalatine Block (incisive foramen beneath incisive papilla) provide palatal soft tissue anesthesia. Pressure anesthesia must be applied for patient comfort.

Anesthetic Pharmacology and Maximum Recommended Dose (MRD) Calculations

Hygienists must accurately calculate Maximum Recommended Doses (MRD) based on patient body weight to prevent lethal toxicity:

• Lidocaine 2% with 1:100,000 Epinephrine: MRD is 3.2 mg/lb (7.0 mg/kg), with an absolute maximum of 500 mg. Each standard 1.8 mL cartridge contains 36 mg of lidocaine (20 mg/mL × 1.8 mL) and 0.018 mg of epinephrine.
• Articaine 4% with 1:100,000 Epinephrine: MRD for a healthy adult is 3.2 mg/lb (7.0 mg/kg). Unlike lidocaine and mepivacaine, the United States labeling for articaine states no separate absolute milligram ceiling for adults — the weight-based figure governs, and clinicians should calculate from body weight rather than relying on a remembered cap. Each standard 1.8 mL cartridge contains 72 mg of articaine (40 mg/mL × 1.8 mL) and 0.018 mg of epinephrine.
• Mepivacaine 3% Plain: MRD is 3.0 mg/lb (6.6 mg/kg), with an absolute maximum of 400 mg. Each 1.8 mL cartridge contains 54 mg of mepivacaine (30 mg/mL × 1.8 mL).

Calculation Protocol: For a 110-lb patient receiving 2% lidocaine:

• Weight-based maximum: 110 lb × 3.2 mg/lb = 352 mg.
• Absolute maximum: 500 mg (use the lower calculated number: 352 mg).
• Maximum cartridges: 352 mg ÷ 36 mg/cartridge = 9.77 cartridges (maximum 9 full cartridges).

Complications and Emergency Management

• Aspiration: Mandatory before any injection. A positive aspiration requires immediate withdrawal, needle change, and re-injection to avoid intravascular toxicity.
• Local Anesthetic Systemic Toxicity (LAST): Caused by inadvertent intravascular injection or absolute overdose. Initial signs include CNS excitation (circumoral numbness, metallic taste, tinnitus, slurred speech, agitation), followed rapidly by CNS depression (tonic-clonic seizures, unconsciousness, respiratory arrest) and cardiovascular collapse. Protocol: stop injection, call 911, maintain airway, deliver 100% oxygen, and initiate basic life support.
• Hematoma: Direct digital pressure applied over the puncture site for at least two minutes, followed by cold compresses.
• Vasovagal Syncope: The most common clinical complication. Place patient in Trendelenburg position (feet elevated above head), ensure open airway, administer 100% oxygen, monitor vitals, and apply cool compresses to the forehead.

Nitrous Oxide-Oxygen Conscious Sedation: Physiology, Fail-Safes, and Diffusion Hypoxia

Nitrous oxide-oxygen (N2O-O2) conscious sedation elevates pain thresholds and alleviates dental anxiety without causing loss of consciousness or depressing protective laryngeal reflexes.

Equipment Safety and Scavenging Standards

• Fail-Safe Mechanism: Contemporary nitrous oxide-oxygen units are built with a fail-safe that prevents delivery of less than 30% oxygen (maximum 70% nitrous oxide), and DHBC-approved nitrous oxide-oxygen analgesia courses teach verification of that fail-safe as part of the pre-use equipment check. If the oxygen supply fails or depletes, the unit shuts off nitrous oxide delivery automatically.
• Scavenging Systems: To prevent occupational chronic exposure (NIOSH standard < 25 ppm ambient N2O), clinical units must incorporate a vacuum scavenging mask with a calibrated exhaust flow rate of 45 to 50 liters per minute (L/min).

Clinical Titration and Oxygen Flush Protocol

1. Pre-Sedation: Establish baseline vital signs and deliver 100% oxygen at a flow rate matching the patient's minute volume (typically 5–7 L/min) for 2 to 3 minutes.
2. Titration: Introduce nitrous oxide in gradual increments of 5% to 10% every 1 to 2 minutes, assessing patient response. Optimal clinical sedation is typically achieved at 30% to 40% N2O.
3. Post-Sedation 100% Oxygen Flush: Upon termination of treatment, the hygienist must turn off nitrous oxide and administer 100% oxygen for a minimum of 5 minutes.
   • Physiological Rationale: Nitrous oxide is poorly soluble in blood. When discontinued, N2O diffuses rapidly from pulmonary capillary blood into the alveoli, diluting alveolar oxygen concentrations. Failing to administer 100% oxygen causes diffusion hypoxia, precipitating acute headaches, lethargy, dizziness, syncope, and nausea.

Soft Tissue Curettage (STC): Definition, Technique, and Surgical Boundaries

Soft tissue curettage is the closed, subgingival debridement and removal of diseased, chronically inflamed crevicular pocket epithelium and inflamed granulation tissue lining the soft tissue wall of a periodontal pocket.

• Clinical Indications: Indicated in cases of persistent, localized gingival inflammation, edema, and bleeding on probing in shallow-to-moderate pockets that have failed to resolve following thorough root planing and plaque control.
• Technique: Following administration of local anesthesia under direct supervision, a sharp curette (such as a Gracey 11/12 or 13/14) is introduced to the base of the pocket with the cutting edge oriented toward the soft tissue wall. Horizontal or circumferential strokes are applied against the pocket wall while supporting the external gingiva with gentle digital counterpressure.
• Statutory Boundary vs. Periodontal Surgery: BPC § 1908(b)(3) strictly prohibits RDHs from performing surgery or cutting hard or soft tissue. Soft tissue curettage is the sole statutory exception authorizing the removal of diseased soft tissue. RDHs are legally forbidden from making surgical incisions, reflecting full-thickness or partial-thickness mucoperiosteal flaps, excising gingival tissue (gingivectomy), or placing sutures.

Advanced Procedures Protocol, Pharmacology, and Safety Parameters